Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome

Table 2

Laboratory findings at presentation.

Case	WBC	Hb	Platelet	LDH	BUN	Cr	Crmax	ADAMTS13	Plasma exchange
	×10^9/L	g/L	×10^9/L	U/L	mg/dL	mg/dL	mg/dL	%	Number of sessions
1	10.1	125	52	3,330	76	2.6	6.5 on day 3	86	17 for 19 days
2*	12.5	85	99	1,271	39	3.37	—	55	15 for 18 days
3	10.48	95	96	1,471	55	4.84	5.99 on day 32	79	1 for 1 day
4-1	13.59	71	65	910	28	2.51	4.02 on day 17	85	6 for 6 days
4-2	5.07	84	63	770	46	5.52	6.86 on day 2	—	0
5**	2.69	111	57	892	71	5.43	5.53 on day 2	74	5 for 6 days

The patient was on hemodialysis at the time of transfer.
**The patient received her last dose of gemcitabine and carboplatin 3 weeks before presentation.
Normal ADAMTS13 activity, >67%; Cr_max: maximal serum creatinine.